Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Robert E. Bellet"'
Autor:
Robert E. Bellet, Gabriel N. Hortobagyi, Richard L. Theriault, Giuseppe Fraschini, Aman U. Buzdar, Frankie A. Holmes, Laura Esparza, Vicente Valero, Ronald S. Walters, Gustavo Fonseca
Publikováno v:
Journal of Clinical Oncology. 13:2886-2894
PURPOSE To determine the efficacy (objective response rate and duration of response and survival) and toxicity of docetaxel in patients with strictly defined anthracycline-resistant metastatic breast cancer (MBC). PATIENTS AND METHODS Thirty-five pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba9372e192e29daf8dabe390c8195b20
https://doi.org/10.1200/jco.1995.13.12.2886
https://doi.org/10.1200/jco.1995.13.12.2886
Autor:
ChauHwei J. Fu, Paula M. Fracasso, Benjamin R. Tan, Ramaswamy Govindan, Jonathan Wildi, Robert E. Bellet, Allison N. Creekmore, Joel Picus, Merrill J. Egorin, Stephen C. Zumbrun, Feng Gao, Sherry A. Goodner, Matthew J. Ellis, Helen S. Pentikis, Gerald P. Linette
Publikováno v:
Cancer chemotherapy and pharmacology. 63(3)
To determine the maximum tolerated dose, dose-limiting toxicity (DLT), and pharmacokinetics of weekly docosahexaenoic acid-paclitaxel (DHA-paclitaxel), a taxane fatty acid conjugate. Docosahexaenoic acid-paclitaxel was administered by 2-hour i.v. inf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36b07ba8d86689c16dc8d5bcce8af2ad
https://pubmed.ncbi.nlm.nih.gov/18414864
https://pubmed.ncbi.nlm.nih.gov/18414864
Autor:
Peter D. Eisenberg, Howard A. Burris, Michael P. Kane, James A. Mortimer, Robert E. Bellet, Eric Genevois, Peter M. Ravdin, William A. Bierman, Gayle Cook
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 13(12)
PURPOSE The purpose of this study was to evaluate the clinical efficacy and safety of docetaxel in patients with metastatic breast cancer (MBC) resistant to doxorubicin or mitoxantrone. PATIENTS AND METHODS Docetaxel 100 mg/m2 was administered as a 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd753106bd136856e0d341101139793f
https://pubmed.ncbi.nlm.nih.gov/8523048
https://pubmed.ncbi.nlm.nih.gov/8523048
Publikováno v:
International journal of cancer. 50(4)
Our experience with the combination of dacarbazine, carmustine, cisplatin with and without tamoxifen is reported. In our initial study, with all 4 drugs, we had an overall response rate of 50% with a complete response rate of 15%. Due to a high incid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03b56dd694c57b81d5b5cf5c3f76f3d7
https://pubmed.ncbi.nlm.nih.gov/1537621
https://pubmed.ncbi.nlm.nih.gov/1537621
Autor:
Robert E. Bellet
Publikováno v:
Journal of the National Cancer Institute. 83(9)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b623996a9d49974fb471dd81d9bbdd1
https://pubmed.ncbi.nlm.nih.gov/2023283
https://pubmed.ncbi.nlm.nih.gov/2023283
Publikováno v:
American Journal of Ophthalmology. 89:567-570
A patient with malignant melanoma of the choroid and ciliary body had a primary cutaneous melanoma and the B-K mole syndrome phenotype. Because of this newly described association, all patients with the B-K mole syndrome (phenotype) should have a com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20e98c9f67e65ec923630904e4e65edf
https://doi.org/10.1016/0002-9394(80)90068-9
https://doi.org/10.1016/0002-9394(80)90068-9
Publikováno v:
Oral Surgery, Oral Medicine, Oral Pathology. 42:73-79
This communication presents the first published case report of a patient with a malignant melanoma of the nasal cavity and maxillary sinus treated with intralesional BCG. In addition, the literature describing the use of intralesional BCG in the trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1fa093ff5ce8c1550ac2b5d08acf737
https://doi.org/10.1016/0030-4220(76)90032-3
https://doi.org/10.1016/0030-4220(76)90032-3
Publikováno v:
Cancer. 63:1292-1295
The combination of dacarbazine (DTIC, 220 mg/m2) and cisplatin (DDP, 25 mg/m2) IV daily for 3 days every 3 weeks, carmustine (BCNU, 150 mg/m2) IV every 6 weeks, and tamoxifen (TAM, 10 mg orally twice daily) produced a 50% objective response rate in p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a0a54d3427562dff2b96ab1ef33e8f1
https://doi.org/10.1002/1097-0142(19890401)63:7<1292::aid-cncr2820630711>3.0.co
https://doi.org/10.1002/1097-0142(19890401)63:7<1292::aid-cncr2820630711>3.0.co
Publikováno v:
Medical and Pediatric Oncology. 4:11-15
Thirty (30) patients with advanced metastatic malignant melanoma refractory to DTIC (NSC-45388) and a nitrosourea were treated with 5-azacytidine (NSC-102816). 5-Azacytidine was administered subcutaneously at a dosage of 100 mg/m2/day for 10 days. Tw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ade104fb05694b9c730f6addd7d72d57
https://doi.org/10.1002/mpo.2950040104
https://doi.org/10.1002/mpo.2950040104
Publikováno v:
Cancer. 31:1170-1175
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1140123db94070bc6788d4ed33c7e289
https://doi.org/10.1002/1097-0142(197305)31:5<1170::aid-cncr2820310520>3.0.co
https://doi.org/10.1002/1097-0142(197305)31:5<1170::aid-cncr2820310520>3.0.co